Overview

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

This is an open label, single-arm, Phase 2 trial to evaluate the anti-tumor activity, safety, and tolerability of Pembrolizumab in combination with azacitidine in subjects with chemo-refractory mCRC without any further standard treatment options Dosage and regimen for all study periods - Pembrolizumab will be given at 200 mg every 21 days. - Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days. The first assessment of tumor response will be performed after cycle 3 (9 weeks), and thereafter approximately every 9 weeks, every 3 cycles of therapy. The modified RECIST 1.1 will be used to establish disease response or progression. All patients will be evaluated and graded for adverse events according to the NCI Common Terminology for Adverse Events, version 4.0 (NCI-CTCAE).

Phase:

Phase 2

Details

Lead Sponsor:

Anuradha Krishnamurthy
University of Pittsburgh

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Azacitidine
Pembrolizumab